137 related articles for article (PubMed ID: 38368946)
1. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment.
Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
[TBL] [Abstract][Full Text] [Related]
2. Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.
Guo J; Yu Z; Sun D; Zou Y; Liu Y; Huang L
Mol Cancer; 2021 Jan; 20(1):10. PubMed ID: 33407548
[TBL] [Abstract][Full Text] [Related]
3. Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis.
Guo J; Yu Z; Das M; Huang L
ACS Nano; 2020 Apr; 14(4):5075-5089. PubMed ID: 32283007
[TBL] [Abstract][Full Text] [Related]
4. Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy.
Guo J; Huang L
Nat Protoc; 2022 Aug; 17(8):1818-1831. PubMed ID: 35650451
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
[TBL] [Abstract][Full Text] [Related]
6. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.
Song W; Shen L; Wang Y; Liu Q; Goodwin TJ; Li J; Dorosheva O; Liu T; Liu R; Huang L
Nat Commun; 2018 Jun; 9(1):2237. PubMed ID: 29884866
[TBL] [Abstract][Full Text] [Related]
7. Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model.
Alimohammadi R; Mahmoodi Chalbatani G; Alimohammadi M; Ghaffari-Nazari H; Rahimi A; Mortaz E; Mossafa N; Boon L; Jalali SA
Sci Rep; 2023 Feb; 13(1):2472. PubMed ID: 36774400
[TBL] [Abstract][Full Text] [Related]
8. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
10. The evolving role of oxaliplatin in the management of colorectal cancer.
de Gramont A; Schmoll HJ; Cervantes A; Tournigand C
Colorectal Dis; 2003 Nov; 5 Suppl 3():10-9. PubMed ID: 23573556
[TBL] [Abstract][Full Text] [Related]
11. [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].
de Gramont A; Tournigand C; Louvet C; André T; Molitor JL; Raymond E; Moreau S; Vignoud J; Le Bail N; Krulik M
Rev Med Interne; 1997; 18(10):769-75. PubMed ID: 9500010
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.
Lim SH; Shim YM; Park SH; Kim HK; Choi YS; Ahn MJ; Park K; Zo JI; Sun JM
Cancer Res Treat; 2017 Jul; 49(3):816-823. PubMed ID: 27857024
[TBL] [Abstract][Full Text] [Related]
13. The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.
Mosconi S; Cascinu S; Zaniboni A; Catalano V; Giordani P; Beretta GD; Martignoni G; Pancera G; Baldelli AM; Poletti P; Curti C; Labianca R
Tumori; 2000; 86(6):465-9. PubMed ID: 11218187
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.
Limagne E; Euvrard R; Thibaudin M; Rébé C; Derangère V; Chevriaux A; Boidot R; Végran F; Bonnefoy N; Vincent J; Bengrine-Lefevre L; Ladoire S; Delmas D; Apetoh L; Ghiringhelli F
Cancer Res; 2016 Sep; 76(18):5241-52. PubMed ID: 27496709
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
[TBL] [Abstract][Full Text] [Related]
16. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
17. Lipid-Polymer Hybrid Nanoparticles with Both PD-L1 Knockdown and Mild Photothermal Effect for Tumor Photothermal Immunotherapy.
Chuan D; Fan R; Chen B; Ren Y; Mu M; Chen H; Zou B; Dong H; Tong A; Guo G
ACS Appl Mater Interfaces; 2023 Sep; 15(36):42209-42226. PubMed ID: 37605506
[TBL] [Abstract][Full Text] [Related]
18. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
Correale P; Cusi MG; Tsang KY; Del Vecchio MT; Marsili S; Placa ML; Intrivici C; Aquino A; Micheli L; Nencini C; Ferrari F; Giorgi G; Bonmassar E; Francini G
J Clin Oncol; 2005 Dec; 23(35):8950-8. PubMed ID: 16061910
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.
Petrioli R; Francini E; Roviello F; Marrelli D; Miano ST; Fiaschi AI; Laera L; Bellini MA; Roviello G
J Geriatr Oncol; 2015 Sep; 6(5):380-6. PubMed ID: 26228711
[TBL] [Abstract][Full Text] [Related]
20. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
